Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) EBIT (2019 - 2025)

Historic EBIT for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$34.4 million.

  • C4 Therapeutics' EBIT fell 2183.83% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$129.8 million, marking a year-over-year decrease of 876.04%. This contributed to the annual value of -$119.6 million for FY2024, which is 1396.6% up from last year.
  • C4 Therapeutics' EBIT amounted to -$34.4 million in Q3 2025, which was down 2183.83% from -$28.5 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' EBIT registered a high of -$15.3 million during Q4 2021, and its lowest value of -$38.3 million during Q4 2022.
  • Moreover, its 5-year median value for EBIT was -$29.2 million (2025), whereas its average is -$29.6 million.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 15101.93% in 2022, then soared by 4292.48% in 2024.
  • C4 Therapeutics' EBIT (Quarter) stood at -$15.3 million in 2021, then plummeted by 151.02% to -$38.3 million in 2022, then grew by 2.26% to -$37.4 million in 2023, then dropped by 0.75% to -$37.7 million in 2024, then grew by 8.74% to -$34.4 million in 2025.
  • Its last three reported values are -$34.4 million in Q3 2025, -$28.5 million for Q2 2025, and -$29.2 million during Q1 2025.